{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:53:53Z","timestamp":1790715233285,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/bjc.2016.427","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T23:47:13Z","timestamp":1483660033000},"page":"356-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival"],"prefix":"10.1038","volume":"116","author":[{"given":"Pauline","family":"Rochefort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Schiffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Polena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Khalil-Mgharbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vilgrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"key":"BFbjc2016427_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.ejca.2013.09.002","volume":"51","author":"M Arnold","year":"2015","unstructured":"Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I (2015) Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 51: 1164\u20131187.","journal-title":"Eur J Cancer"},{"key":"BFbjc2016427_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/sj.bjc.6600956","volume":"88","author":"T Bachelot","year":"2003","unstructured":"Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay J-Y (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88: 1721\u20131726.","journal-title":"Br J Cancer"},{"key":"BFbjc2016427_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00441-014-1843-7","volume":"355","author":"L Bravi","year":"2014","unstructured":"Bravi L, Dejana E, Lampugnani MG (2014) VE-cadherin at a glance. Cell Tissue Res 355: 515\u2013522.","journal-title":"Cell Tissue Res"},{"key":"BFbjc2016427_CR4","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"AM Brufsky","year":"2011","unstructured":"Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O\u2019Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29: 4286\u20134293.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016427_CR5","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10: 7252\u20137259.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2016427_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cncr.11083","volume":"97","author":"J Chang","year":"2003","unstructured":"Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97: 545\u2013553.","journal-title":"Cancer"},{"key":"BFbjc2016427_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","volume":"21","author":"S Dawood","year":"2010","unstructured":"Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21: 2169\u20132174.","journal-title":"Ann Oncol"},{"key":"BFbjc2016427_CR8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1242\/jcs.124529","volume":"126","author":"E Dejana","year":"2013","unstructured":"Dejana E, Orsenigo F (2013) Endothelial adherens junctions at a glance. J Cell Sci 126: 2545\u20132549.","journal-title":"J Cell Sci"},{"key":"BFbjc2016427_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374\u20131403.","journal-title":"Eur J Cancer"},{"key":"BFbjc2016427_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/bjc.2016.66","volume":"114","author":"SA Fry","year":"2016","unstructured":"Fry SA, Robertson CE, Swann R, Dwek MV (2016) Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion. Br J Cancer 114: 1019\u20131026.","journal-title":"Br J Cancer"},{"key":"BFbjc2016427_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.canlet.2012.10.011","volume":"328","author":"SA Fry","year":"2013","unstructured":"Fry SA, Sinclair J, Timms JF, Leathem AJ, Dwek MV (2013) A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer. Cancer Lett 328: 335\u2013344.","journal-title":"Cancer Lett"},{"key":"BFbjc2016427_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.devcel.2013.08.020","volume":"26","author":"M Giannotta","year":"2013","unstructured":"Giannotta M, Trani M, Dejana E (2013) VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell 26: 441\u2013454.","journal-title":"Dev Cell"},{"key":"BFbjc2016427_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/his.12795","volume":"68","author":"Z Kos","year":"2016","unstructured":"Kos Z, Dabbs DJ (2016) Biomarker assessment and molecular testing for prognostication in breast cancer. Histopathology 68: 70\u201385.","journal-title":"Histopathology"},{"key":"BFbjc2016427_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-014-2964-0","volume":"145","author":"ABG Kwast","year":"2014","unstructured":"Kwast ABG, Voogd AC, Menke-Pluijmers MBE, Linn SC, Sonke GS, Kiemeney LA, Siesling S (2014) Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat 145: 503\u2013511.","journal-title":"Breast Cancer Res Treat"},{"key":"BFbjc2016427_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-07-2706","volume":"68","author":"M Labelle","year":"2008","unstructured":"Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G (2008a) Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res 68: 1388\u20131397.","journal-title":"Cancer Res"},{"key":"BFbjc2016427_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-07-2706","volume":"68","author":"M Labelle","year":"2008","unstructured":"Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G (2008b) Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor signaling. Cancer Res 68: 1388\u20131397.","journal-title":"Cancer Res"},{"key":"BFbjc2016427_CR17","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","volume":"19","author":"R Largillier","year":"2008","unstructured":"Largillier R, Ferrero J-M, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19: 2012\u20132019.","journal-title":"Ann Oncol"},{"key":"BFbjc2016427_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BC20110069","volume":"103","author":"A Le Guelte","year":"2011","unstructured":"Le Guelte A, Dwyer J, Gavard J (2011) Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol Cell 103: 593\u2013605.","journal-title":"Biol Cell"},{"key":"BFbjc2016427_CR19","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cort\u00e9s J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239\u20133247.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016427_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10552-008-9252-4","volume":"20","author":"KW Reeves","year":"2009","unstructured":"Reeves KW, Ness RB, Stone RA, Weissfeld JL, Vogel VG, Powers RW, Modugno F, Cauley JA (2009) Vascular endothelial growth factor and breast cancer risk. Cancer Causes Control 20: 375\u2013386.","journal-title":"Cancer Causes Control"},{"key":"BFbjc2016427_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Di\u00e9ras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SYT, Zhou X, Phan S-C, O\u2019Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252\u20131260.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016427_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/A:1008384019411","volume":"12","author":"M Ryberg","year":"2001","unstructured":"Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P (2001) Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12: 81\u201387.","journal-title":"Ann Oncol"},{"key":"BFbjc2016427_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11523-014-0334-9","volume":"10","author":"O Tr\u00e9dan","year":"2015","unstructured":"Tr\u00e9dan O, Lacroix-Triki M, Guiu S, Mouret-Reynier M-A, Barri\u00e8re J, Bidard F-C, Braccini A-L, Mir O, Villanueva C, Barth\u00e9l\u00e9my P (2015) Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol 10: 189\u2013198.","journal-title":"Target Oncol"},{"key":"BFbjc2016427_CR24","doi-asserted-by":"publisher","first-page":"e80056","DOI":"10.1371\/journal.pone.0080056","volume":"8","author":"I Vilgrain","year":"2013","unstructured":"Vilgrain I, Sidib\u00e9 A, Polena H, Cand F, Mannic T, Arboleas M, Boccard S, Baudet A, Gulino-Debrac D, Bouillet L, Quesada J-L, Mendoza C, Lebas J-F, Pelletier L, Berger F (2013) Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. PLoS One 8: e80056.","journal-title":"PLoS One"},{"key":"BFbjc2016427_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tcm.2005.11.008","volume":"16","author":"Y Wallez","year":"2006","unstructured":"Wallez Y, Vilgrain I, Huber P (2006) Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16: 55\u201359.","journal-title":"Trends Cardiovasc Med"},{"key":"BFbjc2016427_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/sj.onc.1209855","volume":"26","author":"Y Wallez","year":"2007","unstructured":"Wallez Y, Cand F, Cruzalegui F, Wernstedt C, Souchelnytskyi S, Vilgrain I, Huber P (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26: 1067\u20131077.","journal-title":"Oncogene"},{"key":"BFbjc2016427_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199101033240101","volume":"324","author":"N Weidner","year":"1991","unstructured":"Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis\u2014correlation in invasive breast carcinoma. N Engl J Med 324: 1\u20138.","journal-title":"N Engl J Med"},{"key":"BFbjc2016427_CR28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1200\/JCO.1998.16.7.2401","volume":"16","author":"N Yamamoto","year":"1998","unstructured":"Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I, Takashima S (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401\u20132408.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016427","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:36:00Z","timestamp":1684416960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFbjc2016427"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.427","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"22 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}